Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: oldcoach19 who wrote (1788)	3/29/2016 11:44:04 AM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

OC, you asked on ihub why would anybody be buying this morning. Here is my cup is half full view. If I did not have so many shares, I would be buying a few. Remember that the ED market is truly a multibillion dollar market and Vitaros treats that portion of the market that is not effectively treated by Viagra, Cialis, etc., regardless of how cheap these PED5 pills are. Further, the company now has US rights back, a market (unlike any place else in the world except New Zealand) where advertising is allowed. Finally, the company is committed to cutting costs immediately and does not face the uncertainty of how to raise perhaps $30 million or more for clinical trials for a drug (Fis) that may not succeed...and now we know it would not have succeeded. Vitaros approval in the US is a much better bet with thousands of users in Europe and without reported adverse effects. European use of Vitaros is increasing quarter over quarter. The unknown is what Pfizer/Allergan will do if/when Vitaros receives US approval. If Pfizer decides to aggressively market Vitaros, Apricus should do quite well. If not, Apricus will have to enter into another alliance in order to market Vitaros.